GLUE

Monte Rosa Therapeutics Inc

GLUE.US monterosatx.com + Research + Basket
CIK 0001826457
Employees 173
Phone 617 949 2643
Fiscal year end December
IPO Jun 24, 2021
Address 321 Harrison Avenue, Boston, MA, United States, 02118
10.76
-0.11 (-1.01%)
USD · NASDAQ
52-week range
9.68
25.77
Trading at 7% of the 52-week range
Market Cap
927.36M
P/E Ratio
0.00
Forward P/E
10.02
Book Value
5.72
Div. Yield
N/A
% Institutions
116.49%
% Insiders
0.561%

1 Year

-17.3%

3 Year

+216.5%

10 Year

-49.2%
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Actions

Add an action for GLUE.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Markus Warmuth M.D. President, CEO & Director 1971
Mr. Philip Nickson J.D., Ph.D. Chief Business & Legal Officer 1979
Mr. Filip Janku M.D., Ph.D. Chief Medical Officer 1974
Mr. Matthew Bowen Corporate Controller & Principal Accounting Officer 1989
Ms. Jennifer Champoux Chief Operating Officer 1972
Mr. Magnus Walter DPHIL Chief Technology Officer NA
Dr. John C. Castle Ph.D. Chief Data & Information Officer 1971
Dr. Sharon Townson Ph.D. Chief Scientific Officer 1975
Mr. Andrew Funderburk Chief Investor Relations and Strategy Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 09, 2026 Philip Nickson N/A Sale 5.85K $17.69 $103.40K SEC
Mar 04, 2026 Edmund Dunn N/A Sale 139.00 $17.96 $2.50K SEC
Mar 02, 2026 Edmund Dunn N/A Sale 536.00 $17.50 $9.38K SEC
Mar 02, 2026 Markus Warmuth N/A Sale 5.47K $17.92 $97.95K SEC
Feb 27, 2026 Edmund Dunn N/A Sale 25.16K $18.10 $455.47K SEC
Jan 07, 2026 Markus Warmuth N/A Sale 5.47K $23.49 $128.40K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
T. Rowe Price Associates, Inc. 8.86M Jun 30, 2026 11.28% $0.02 31.86%
NEA Management Company, LLC 7.69M Jun 30, 2026 9.79% $11.72 0.00%
BlackRock Inc 6.84M Jun 30, 2026 8.71% $0.00 21.38%
TCG Crossover Management, LLC 4.62M Jun 30, 2026 5.88% $2.69 0.00%
Vestal Point Capital LP 4.60M Jun 30, 2026 5.86% $2.60 27.65%
Bvf Inc 4.46M Jun 30, 2026 5.68% $2.76 0.00%
Baker Bros Advisors LP 4.35M Jun 30, 2026 5.53% $0.53 0.00%
State Street Corp 3.73M Jun 30, 2026 4.75% $0.00 11.25%
Suvretta Capital Management, LLC 3.55M Jun 30, 2026 4.52% $1.57 -16.02%
Vanguard Capital Management, LLC 3.41M Jun 30, 2026 4.35% $0.00 10.09%
Versant Venture Management LLC 3.18M Jun 30, 2026 4.05% $47.34 0.00%
BRAIDWELL LP 2.45M Jun 30, 2026 3.12% $2.19 -23.55%
Geode Capital Management, LLC 1.86M Jun 30, 2026 2.37% $0.00 20.98%
American Century Companies Inc 1.62M Jun 30, 2026 2.07% $0.02 -42.24%
Marshall Wace Asset Management Ltd 1.59M Jun 30, 2026 2.03% $0.03 11.20%
Aisling Capital Management LP 1.56M Jun 30, 2026 1.98% $7.98 0.00%
Nantahala Capital Management, LLC 1.30M Jun 30, 2026 1.66% $0.52 100.00%
Bellevue Group AG 1.19M Jun 30, 2026 1.52% $0.61 -4.80%
Dimensional Fund Advisors, Inc. 1.18M Jun 30, 2026 1.50% $0.01 13.07%
MPM Oncology Impact Management LP 1.16M Jun 30, 2026 1.48% $1.71 -1.35%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 2.56M 3.26% ▲ 0.00% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 2.12M 2.70% ▼ 1.88% Sep 30, 2026
3 T. Rowe Price New Horizons 1.98M 2.52% ▼ 11.03% Sep 30, 2026
4 iShares Russell 2000 ETF 1.92M 2.44% ▼ 1.14% Sep 30, 2026
5 HBM Healthcare Investments AG Ord 1.82M 2.32% ▲ 0.00% Jun 30, 2026
6 T. Rowe Price Integrated US Sm Gr Eq 1.48M 1.88% ▲ 0.00% Sep 30, 2026
7 Fidelity Small Cap Index 809.64K 1.03% ▲ 0.90% Jul 31, 2026
8 T. Rowe Price Health Sciences 748.51K 0.95% ▲ 0.00% Sep 30, 2026
9 iShares Russell 2000 Growth ETF 694.65K 0.88% ▼ 0.13% Sep 30, 2026
10 MEDICAL BioHealth EUR Acc 611.63K 0.78% ▲ 0.02% Aug 31, 2026

Financial Highlights

▼
Market Cap: $927.36M
EBITDA: $-173.73M
Book Value: $5.72
Earnings/Share: $-1.75
Profit Margin: 0.00%
Operating Margin: -547.84%
ROA (TTM): -21.63%
ROE (TTM): -42.66%
Revenue (TTM): $28.73M
Revenue/Share (TTM): $0.31
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -61.30%

Valuation Metrics

Enterprise Value: $345.52M
Trailing P/E: 0.00
Forward P/E: 10.02

Shares Statistics

Shares Outstanding: 85.31M
Shares Float: 54.48M
% Insiders: 0.561%
% Institutions: 116.49%
Shares Short: 20.66M
Shares Short (Prior Month): 19.69M
Short Ratio: 14.00
Short % Float: 24.60%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$123.67M
Cost of Goods Sold
adjust
$-8.36M
Gross Profit
subtotal
$115.32M
SG&A
adjust
$-36.38M
R&D
adjust
$-141.50M
Operating Income
subtotal
$-54.21M
Other / Non-Operating Items
adjust
$15.58M
Net Income
subtotal
$-38.63M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GLUE.US!